Most transgender boys reach their predicted adult height after treatment with gonadotropin-releasing hormone analogues and testosterone therapy, according to data published in The Journal of Clinical ...
ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in the Phase 3 HERO study Conference call and webcast to be held on December 21 ...
Gonadotropin-releasing hormone (GnRH) therapy improves cognitive function in Down syndrome (DS) mouse models and male patients with DS, according to a new study. The findings reveal a previously ...
IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus ...
Gonadotropin-releasing hormone (GnRH) therapy improves cognitive function in Down syndrome (DS) mouse models and male patients with DS, according to a new study. The findings reveal a previously ...
Phase II trial of nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC) No significant financial relationships to disclose. This is ...
Chemotherapy poses the highest risk for early menopause, particularly in women over 40, while radiation does not impact ...
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) le ...
ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels (Conference call and webcast to be held on December 21 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time “I ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback